Concepedia

Publication | Open Access

The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer

DOIFull Paper Access

48

Citations

9

References

2016

Year

Ofer N. Gofrit, Vladimir Yutkin, Amos Shapiro, Galina Pizov, Kevin C. Zorn, Guy Hidas, Ilan Gielchinsky, Mordechai Duvdevani, Ezekiel H. Landau, Dov Pode
Frontiers in Oncology

Abstract

A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC.

References

YearCitations

Page 1